Veristat appoints James Roach as chief medical officer
Dr. Roach joins Veristat with over 20 years of experience supporting clinical development, registration, commercialization and product lifecycle strategy at several biotechnology, pharmaceutical and clinical research firms.
He brings a diverse background of therapeutic experience that strategically aligns with Veristat’s core therapeutic areas of Oncology, Rare Diseases, CNS disorders and Cardiovascular disease.
Additionally, his expertise with Autoimmune/Inflammation will be instrumental to expanding that knowledge base.
Throughout his career, he has built and led clinical research, clinical development operations, medical affairs, and regulatory affairs teams, working in unison to bring numerous products through the regulatory submission process.
Most recently, Dr. Roach served as Senior Vice President of Development and Chief Medical Officer at Momenta Pharmaceuticals and prior was the Senior Vice President of Medical Affairs at Sepracor Inc.
He has also held leadership roles in Clinical Research and Medical Affairs at Millennium Pharmaceuticals, LeukoSite, Inc (acquired by Millennium) and Astra USA, and also led the Medical Affairs, Safety/Pharmacovigilance and Medical Monitoring functions at Medical and Technical Research Associates (MTRA), a contract research organization acquired by AAI Pharma.
Dr. Roach has also maintained an academic appointment at Harvard Medical School and has been an Associate Physician at Brigham and Women’s Hospital (BWH) and member of the BWH Pulmonary and Critical Care Medicine Division since 1993. ■
LATEST MOVES FROM Massachusetts
- RXi Pharmaceuticals appoints Jonathan Freeman as director
- Corero promotes Andrew Lloyd to executive role
- AMAG Pharmaceuticals appoints Brian Kelley to board
- Visal Leng named president and CEO, Asia Pacific, GE Oil & Gas
- Dynatrace appoints Kevin Burns as CFO
More inside POST
Red Hat Q2 revenue up 21% in USD Earnings
Oracle posts 14% gain in Q1 earnings Earnings